Specificities of autoinhibitory domain peptides for four protein kinases: Implications for intact cell studies of protein kinase function

M. Kevin Smith, Roger J. Colbran, Thomas Soderling

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Synthetic peptides corresponding to the autoinhibitory domains of calcium/calmodulin-dependent protein kinase II (CaMK-(281-309)), smooth muscle myosin light chain kinase (MLCK-(480-501)), and protein kinase C (PKC-(19-36)) as well as a peptide derived from the heat-stable inhibitor of cAMP-dependent protein kinase (PKI-tide) were tested for their inhibitory specificities. The inhibitory potencies of the four peptides were determined for each of the four protein kinases using both peptide substrates (at approximate Km, concentrations) and protein substrates (at concentrations less than Km). In agreement with previous studies PKI-tide was a specific and potent inhibitor of only cAMP kinase, and none of the other inhibitory peptides gave significant inhibition of cAMP kinase at concentrations of less than 100 μM. With synthetic peptide substrates, PKC-(19-36) strongly inhibited native PKC (IC50 <1 μM) but also significantly inhibited autophosphorylated CaMK-II (IC50 = 30 μM) and proteolytically activated MLCK (IC50 = 35 μM). MLCK-(480-501) potently inhibited MLCK (IC50 = 0.25 μM) and also strongly inhibited both PKC and CaMK-II (IC50 = 1.4 and 1.7 μM, respectively). CaMK-(281-309) inhibited autophosphorylated CaMK-II, PKC, and proteolyzed MLCK almost equally (IC50 = 10, 38, and 48 μM, respectively). Qualitatively similar results were obtained with protein substrates. These studies validate the use of PKI-tide as a specific inhibitor of cAMP kinase in intact cell studies and suggest that PKC-(19-36) can also be used but only within a narrow concentration range. However, the autoinhibitory domain peptides from MLCK and CaMK-II are not sufficiently specific to be used in similar investigations.

Original languageEnglish (US)
Pages (from-to)1837-1840
Number of pages4
JournalJournal of Biological Chemistry
Volume265
Issue number4
StatePublished - Feb 5 1990
Externally publishedYes

Fingerprint

Protein Kinases
Inhibitory Concentration 50
Peptides
Tides
Calcium-Calmodulin-Dependent Protein Kinase Type 2
Phosphotransferases
Substrates
Smooth Muscle Myosins
Myosin-Light-Chain Kinase
Calcium-Calmodulin-Dependent Protein Kinases
Cyclic AMP-Dependent Protein Kinases
Protein Kinase C
Protein Domains
Proteins
Hot Temperature
protein kinase C (19-36)
SM 1

ASJC Scopus subject areas

  • Biochemistry

Cite this

Specificities of autoinhibitory domain peptides for four protein kinases : Implications for intact cell studies of protein kinase function. / Smith, M. Kevin; Colbran, Roger J.; Soderling, Thomas.

In: Journal of Biological Chemistry, Vol. 265, No. 4, 05.02.1990, p. 1837-1840.

Research output: Contribution to journalArticle

@article{1b850512ae43448a91842a601e674fec,
title = "Specificities of autoinhibitory domain peptides for four protein kinases: Implications for intact cell studies of protein kinase function",
abstract = "Synthetic peptides corresponding to the autoinhibitory domains of calcium/calmodulin-dependent protein kinase II (CaMK-(281-309)), smooth muscle myosin light chain kinase (MLCK-(480-501)), and protein kinase C (PKC-(19-36)) as well as a peptide derived from the heat-stable inhibitor of cAMP-dependent protein kinase (PKI-tide) were tested for their inhibitory specificities. The inhibitory potencies of the four peptides were determined for each of the four protein kinases using both peptide substrates (at approximate Km, concentrations) and protein substrates (at concentrations less than Km). In agreement with previous studies PKI-tide was a specific and potent inhibitor of only cAMP kinase, and none of the other inhibitory peptides gave significant inhibition of cAMP kinase at concentrations of less than 100 μM. With synthetic peptide substrates, PKC-(19-36) strongly inhibited native PKC (IC50 <1 μM) but also significantly inhibited autophosphorylated CaMK-II (IC50 = 30 μM) and proteolytically activated MLCK (IC50 = 35 μM). MLCK-(480-501) potently inhibited MLCK (IC50 = 0.25 μM) and also strongly inhibited both PKC and CaMK-II (IC50 = 1.4 and 1.7 μM, respectively). CaMK-(281-309) inhibited autophosphorylated CaMK-II, PKC, and proteolyzed MLCK almost equally (IC50 = 10, 38, and 48 μM, respectively). Qualitatively similar results were obtained with protein substrates. These studies validate the use of PKI-tide as a specific inhibitor of cAMP kinase in intact cell studies and suggest that PKC-(19-36) can also be used but only within a narrow concentration range. However, the autoinhibitory domain peptides from MLCK and CaMK-II are not sufficiently specific to be used in similar investigations.",
author = "Smith, {M. Kevin} and Colbran, {Roger J.} and Thomas Soderling",
year = "1990",
month = "2",
day = "5",
language = "English (US)",
volume = "265",
pages = "1837--1840",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "4",

}

TY - JOUR

T1 - Specificities of autoinhibitory domain peptides for four protein kinases

T2 - Implications for intact cell studies of protein kinase function

AU - Smith, M. Kevin

AU - Colbran, Roger J.

AU - Soderling, Thomas

PY - 1990/2/5

Y1 - 1990/2/5

N2 - Synthetic peptides corresponding to the autoinhibitory domains of calcium/calmodulin-dependent protein kinase II (CaMK-(281-309)), smooth muscle myosin light chain kinase (MLCK-(480-501)), and protein kinase C (PKC-(19-36)) as well as a peptide derived from the heat-stable inhibitor of cAMP-dependent protein kinase (PKI-tide) were tested for their inhibitory specificities. The inhibitory potencies of the four peptides were determined for each of the four protein kinases using both peptide substrates (at approximate Km, concentrations) and protein substrates (at concentrations less than Km). In agreement with previous studies PKI-tide was a specific and potent inhibitor of only cAMP kinase, and none of the other inhibitory peptides gave significant inhibition of cAMP kinase at concentrations of less than 100 μM. With synthetic peptide substrates, PKC-(19-36) strongly inhibited native PKC (IC50 <1 μM) but also significantly inhibited autophosphorylated CaMK-II (IC50 = 30 μM) and proteolytically activated MLCK (IC50 = 35 μM). MLCK-(480-501) potently inhibited MLCK (IC50 = 0.25 μM) and also strongly inhibited both PKC and CaMK-II (IC50 = 1.4 and 1.7 μM, respectively). CaMK-(281-309) inhibited autophosphorylated CaMK-II, PKC, and proteolyzed MLCK almost equally (IC50 = 10, 38, and 48 μM, respectively). Qualitatively similar results were obtained with protein substrates. These studies validate the use of PKI-tide as a specific inhibitor of cAMP kinase in intact cell studies and suggest that PKC-(19-36) can also be used but only within a narrow concentration range. However, the autoinhibitory domain peptides from MLCK and CaMK-II are not sufficiently specific to be used in similar investigations.

AB - Synthetic peptides corresponding to the autoinhibitory domains of calcium/calmodulin-dependent protein kinase II (CaMK-(281-309)), smooth muscle myosin light chain kinase (MLCK-(480-501)), and protein kinase C (PKC-(19-36)) as well as a peptide derived from the heat-stable inhibitor of cAMP-dependent protein kinase (PKI-tide) were tested for their inhibitory specificities. The inhibitory potencies of the four peptides were determined for each of the four protein kinases using both peptide substrates (at approximate Km, concentrations) and protein substrates (at concentrations less than Km). In agreement with previous studies PKI-tide was a specific and potent inhibitor of only cAMP kinase, and none of the other inhibitory peptides gave significant inhibition of cAMP kinase at concentrations of less than 100 μM. With synthetic peptide substrates, PKC-(19-36) strongly inhibited native PKC (IC50 <1 μM) but also significantly inhibited autophosphorylated CaMK-II (IC50 = 30 μM) and proteolytically activated MLCK (IC50 = 35 μM). MLCK-(480-501) potently inhibited MLCK (IC50 = 0.25 μM) and also strongly inhibited both PKC and CaMK-II (IC50 = 1.4 and 1.7 μM, respectively). CaMK-(281-309) inhibited autophosphorylated CaMK-II, PKC, and proteolyzed MLCK almost equally (IC50 = 10, 38, and 48 μM, respectively). Qualitatively similar results were obtained with protein substrates. These studies validate the use of PKI-tide as a specific inhibitor of cAMP kinase in intact cell studies and suggest that PKC-(19-36) can also be used but only within a narrow concentration range. However, the autoinhibitory domain peptides from MLCK and CaMK-II are not sufficiently specific to be used in similar investigations.

UR - http://www.scopus.com/inward/record.url?scp=0025088506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025088506&partnerID=8YFLogxK

M3 - Article

C2 - 2153665

AN - SCOPUS:0025088506

VL - 265

SP - 1837

EP - 1840

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 4

ER -